Publications
Publications
- 2024
- HBS Working Paper Series
Tamoxifen—Reducing Breast Cancer Risks: Case Histories of Transformational Advances
By: Amar Bhidé, Srikant Datar and Katherine Stebbins
Abstract
We describe the development of tamoxifen, considered a “gold standard” treatment for
millions of breast cancer patients. Specifically, we describe breast cancer treatments before tamoxifen’s
development; the initial development of tamoxifen from 1960 to 1973; tamoxifen’s adoption as an
adjuvant breast cancer treatment between 1973 and 1985; and the extension of tamoxifen’s use to
include preventative treatment, between 1986 and 2002.
Keywords
Health Care and Treatment; Technological Innovation; Innovation and Invention; Innovation Strategy; Technology Adoption; Collaborative Innovation and Invention; Governing Rules, Regulations, and Reforms
Citation
Bhidé, Amar, Srikant Datar, and Katherine Stebbins. "Tamoxifen—Reducing Breast Cancer Risks: Case Histories of Transformational Advances." Harvard Business School Working Paper, No. 20-134, July 2020. (Revised May 2024.)